A randomized controlled trial of nebulized surfactant for the treatment of severe COVID-19 in adults (COVSurf trial).
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
28 Nov 2023
28 Nov 2023
Historique:
received:
22
09
2023
accepted:
16
11
2023
medline:
30
11
2023
pubmed:
29
11
2023
entrez:
28
11
2023
Statut:
epublish
Résumé
SARS-CoV-2 directly targets alveolar epithelial cells and can lead to surfactant deficiency. Early reports suggested surfactant replacement may be effective in improving outcomes. The aim of the study to assess the feasibility and efficacy of nebulized surfactant in mechanically ventilated COVID-19 patients. Patients were randomly assigned to receive open-labelled bovine nebulized surfactant or control (ratio 3-surfactant: 2-control). This was an exploratory dose-response study starting with 1080 mg of surfactant delivered at 3 time points (0, 8 and 24 h). After completion of 10 patients, the dose was reduced to 540 mg, and the frequency of nebulization was increased to 5/6 time points (0, 12, 24, 36, 48, and an optional 72 h) on the advice of the Trial Steering Committee. The co-primary outcomes were improvement in oxygenation (change in PaO
Identifiants
pubmed: 38017061
doi: 10.1038/s41598-023-47672-x
pii: 10.1038/s41598-023-47672-x
pmc: PMC10684757
doi:
Substances chimiques
Pulmonary Surfactants
0
Surface-Active Agents
0
Types de publication
Randomized Controlled Trial
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
20946Subventions
Organisme : Bill & Melinda Gates Foundation
ID : INV-016631
Pays : United States
Informations de copyright
© 2023. The Author(s).
Références
BMJ Open Respir Res. 2019 May 24;6(1):e000420
pubmed: 31258917
Biochim Biophys Acta. 2013 Mar;1831(3):612-25
pubmed: 23026158
J Med Virol. 2020 Oct;92(10):1733-1734
pubmed: 32242950
Am J Respir Crit Care Med. 2021 Jan 1;203(1):54-66
pubmed: 33119402
Pharm Res. 2017 Feb;34(2):290-300
pubmed: 27822851
J Innate Immun. 2019;11(1):13-28
pubmed: 30293076
Am J Respir Crit Care Med. 2022 Feb 15;205(4):471-473
pubmed: 34874818
Pulm Pharmacol Ther. 2003;16(6):327-33
pubmed: 14580923
Pediatrics. 2014 Jan;133(1):156-63
pubmed: 24379227
Sci Rep. 2020 Nov 10;10(1):19395
pubmed: 33173052
Respir Res. 2021 Jan 18;22(1):20
pubmed: 33461535
Sci Rep. 2022 Mar 8;12(1):4040
pubmed: 35260704
Arch Dis Child Fetal Neonatal Ed. 2022 Jan;107(1):51-55
pubmed: 34112722
Lancet Respir Med. 2020 Apr;8(4):420-422
pubmed: 32085846
Can J Biochem Physiol. 1959 Aug;37(8):911-7
pubmed: 13671378
Crit Care Explor. 2021 Feb 15;3(2):e0338
pubmed: 33604579
Iran J Pharm Res. 2021 Summer;20(3):553-559
pubmed: 34904008
JAMA. 2016 Feb 23;315(8):788-800
pubmed: 26903337
Nat Rev Microbiol. 2021 Mar;19(3):155-170
pubmed: 33116300
BMJ Open Respir Res. 2021 Sep;8(1):
pubmed: 34521648
Ther Adv Respir Dis. 2020 Jan-Dec;14:1753466620951043
pubmed: 32865137
BMC Pulm Med. 2019 Jan 9;19(1):9
pubmed: 30626363
Cell. 2020 May 28;181(5):1016-1035.e19
pubmed: 32413319
Intensive Care Med. 2020 Jun;46(6):1099-1102
pubmed: 32291463
J Clin Med. 2022 Jun 21;11(13):
pubmed: 35806862
Am J Respir Crit Care Med. 2019 Dec 1;200(11):1363-1372
pubmed: 31356105
Cochrane Database Syst Rev. 2000;(2):CD000144
pubmed: 10796308
Am J Respir Crit Care Med. 2020 Aug 15;202(4):624-626
pubmed: 32579022
BMC Pulm Med. 2014 Feb 01;14:10
pubmed: 24484629
Scand J Clin Lab Invest. 2020 Nov;80(7):536-540
pubmed: 32804580
Pulmonology. 2018 Feb 2;:
pubmed: 29398628
Respir Med. 2021 Aug-Sep;185:106489
pubmed: 34087610
N Engl J Med. 1996 May 30;334(22):1417-21
pubmed: 8618579
Respir Res. 2014 Nov 07;15:128
pubmed: 25378080
Diagnostics (Basel). 2023 Sep 15;13(18):
pubmed: 37761330
Pediatr Pulmonol. 1998 Aug;26(2):125-8
pubmed: 9727764
Trials. 2020 Dec 10;21(1):1014
pubmed: 33302976
N Engl J Med. 2014 Oct 30;371(18):1695-703
pubmed: 25268516
Crit Care. 2012 Nov 22;16(6):238
pubmed: 23171712